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Abstract
Many aspects of cellular physiology remain unstudied in somatic stem cells. For example, there
are almost no data on protein synthesis in any somatic stem cell. We found that the amount of
protein synthesized per hour in haematopoietic stem cells (HSCs) in vivo was lower than in most
other haematopoietic cells, even if we controlled for differences in cell cycle status or forced
HSCs to undergo self-renewing divisions. Reduced ribosome function in Rpl24Bst/+ mice further
reduced protein synthesis in HSCs and impaired HSC function. Pten deletion increased protein
synthesis in HSCs but also reduced HSC function. Rpl24Bst/+ cell-autonomously rescued the
effects of Pten deletion in HSCs, blocking the increase in protein synthesis, restoring HSC
function, and delaying leukaemogenesis. Pten deficiency thus depletes HSCs and promotes
leukaemia partly by increasing protein synthesis. Either increased or decreased protein synthesis
impairs HSC function.
Mutations in ribosomes and other gene products that affect protein synthesis are associated
with human diseases marked by haematopoietic dysfunction1,2. Increased protein synthesis
can promote the development and progression of certain cancers, including haematopoietic
malignancies3–6. Ribosomal defects commonly impair HSC and erythroid progenitor
function7–11. However, it is not clear whether these defects reflect a catastrophic reduction
in protein synthesis below the level required for cellular homeostasis or whether HSCs
require highly regulated protein synthesis.
Methods for measuring protein synthesis have depended upon the incorporation of
radiolabeled amino acids, amino acid analogues12, or puromycin13–15 into nascent
polypeptides in cultured cells. However, somatic stem cells profoundly change their
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tproperties in culture16 necessitating the analysis of protein synthesis in rare cells in vivo. A
new fluorogenic assay using O-propargyl-puromycin (OP-Puro) has been developed to
image protein synthesis in vivo17. OP-Puro, like puromycin, is taken up by cells in vivo,
entering ribosome acceptor sites and incorporating into nascent polypeptides17. An azide-
alkyne reaction can be used to fluorescently label OP-Puro to quantitate protein synthesis in
individual cells17. We adapted this approach to quantify protein synthesis by haematopoietic
cells using flow cytometry.
HSCs synthesize less protein per hour
We administered a single intraperitoneal injection of OP-Puro (50mg/kg body mass) then
sacrificed mice one hour later and isolated bone marrow cells. We did not detect toxicity,
signs of illness, changes in bone marrow cellularity, or changes in the frequencies of
CD150+CD48−Lineage−Sca-1+c-kit+ (CD150+CD48−LSK) HSCs18, Annexin V+ bone
marrow cells, Annexin V+ HSCs, or dividing HSCs (Extended Data Fig. 1a–e).
Bone marrow cells from OP-Puro treated mice exhibited a clear increase in fluorescence
relative to untreated mice (Fig. 1a). The translation inhibitor, cycloheximide, profoundly
blocked OP-Puro incorporation by bone marrow cells in culture (Fig. 1b). Incorporation of
the methionine analogues, L-homopropargylglycine (HPG) and L-azidohomoalanine
(AHA), into bone marrow cells, common myeloid progenitors (CMPs), granulocyte-
macrophage progenitors (GMPs), and Gr-1+ myeloid cells correlated with OP-Puro
incorporation in culture (Fig. 1c–f).
HSCs incorporated less OP-Puro than most other bone marrow cells from the same mice
(Fig. 1g). This suggested that HSCs synthesize less protein per hour than most other
haematopoietic progenitors. CD150−CD48−LSK multipotent progenitors (MPPs)19
exhibited similar OP-Puro incorporation as HSCs (Fig. 1h); however, the mean rate of OP-
Puro incorporation was significantly higher in unfractionated bone marrow cells, CMPs,
GMPs, megakaryocyte-erythroid progenitors (MEPs), Gr-1+ myeloid cells,
B220+IgM−CD43+ pro-B cells, B220+IgM−CD43− pre-B cells, B220+IgM+ B cells, CD3+ T
cells, and CD71+Ter119+ erythroid progenitors (Fig. 1h). Extended Data Figures 1f–i show
markers, gating strategies, and OP-Puro incorporation histograms for each cell population.
To test whether reduced OP-Puro incorporation into HSCs reflects OP-Puro efflux by the
Abcg2/Bcrp1 transporter we administered OP-Puro to Abcg2-deficient mice, which lack
efflux activity in HSCs20. Abcg2−/− HSCs continued to exhibit significantly lower mean
rates of OP-Puro incorporation as compared to most other Abcg2−/− progenitors (Fig. 2a),
similar to the lowest levels observed among bone marrow cells (Fig. 2b).
Differences in OP-Puro incorporation did not reflect proteasomal degradation21. The
maximum OP-Puro signal in haematopoietic cells was one hour after OP-Puro
administration (data not shown). However, HSCs exhibited little decline in OP-Puro signal
between 1 and 3 hours after administration and had significantly less OP-Puro incorporation
than any restricted progenitor at both times (Fig. 2c). In contrast, the OP-Puro signal was
profoundly reduced 24 hours after administration (Fig. 2c). This suggested that degradation
of OP-Puro-containing polypeptides requires several hours. Consistent with this, incubation
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fluorescence in any cell population relative to an aliquot of the same cells kept on ice to
arrest degradation (Extended Data Fig. 2a).
We pre-treated mice with bortezomib (1mg/kg i.v.) to inhibit proteasome activity22 one hour
before OP-Puro administration. This significantly increased the OP-Puro signal in nearly all
cell populations 24 hours after OP-Puro administration (Extended Data Fig. 2b). When we
assessed OP-Puro incorporation one hour after administration, bortezomib pre-treatment
only modestly increased OP-Puro fluorescence in certain cell populations (Fig. 2d). Even in
the presence of bortezomib, HSCs had significantly less OP-Puro fluorescence than
restricted progenitors. The lower OP-Puro incorporation by HSCs appears to primarily
reflect reduced protein synthesis rather than accelerated proteosomal degradation.
OP-Puro also did not affect the levels of phosphorylated 4E-BP1 or eIF2α (Fig. 2e), key
regulators of translation that can be influenced by proteotoxic stress23,24. HSC/MPPs had
less p4E-BP1 and β-actin per cell than other hematopoietic cells but similar levels of total
4E-BP1. This raised the possibility that HSCs synthesize less protein as a consequence of
increased 4E-BP1-mediated inhibition of translation (Fig. 2e).
Doubling the dose of OP-Puro to 100mg/kg significantly increased OP-Puro incorporation in
all cell populations, but HSCs continued to have significantly lower levels than all other cell
populations except MPPs (Fig. 2f). Thus, 50mg/kg OP-Puro did not significantly attenuate
protein synthesis and uptake was not saturated in HSCs or most other cells.
Even dividing HSCs make less protein
Haematopoietic progenitors in S/G2/M exhibited significantly higher rates of OP-Puro
incorporation than cells in G0/G1 (Fig. 3a, b). Total protein was also higher in Gr-1+ cells
and bone marrow cells in S/G2/M as compared to G0/G1 (Extended Data Fig. 3b). However,
HSCs and MPPs exhibited less OP-Puro incorporation than restricted progenitors even when
we compared only cells in G0/G1 (Fig. 3b). We treated mice with cyclophosphamide (Cy)
followed by two daily injections of granulocyte colony stimulating factor (G-CSF) to induce
self-renewing divisions by HSCs (Extended Data Fig. 3d)25. Cy/G-CSF also increased
division by MPPs, Gr-1+ cells, and IgM+ B cells (Extended Data Fig. 3a, e). Each of these
populations exhibited increased OP-Puro incorporation after Cy/G-CSF treatment (Fig. 3c).
However, HSCs had significantly less protein synthesis as compared to most restricted
progenitors irrespective of whether we compared S/G2/M cells (Fig. 3e) or G0/G1 cells (Fig.
3d, Extended Data Fig. 3f, g) from Cy/G-CSF-treated mice.
Differences in protein synthesis between HSCs and restricted progenitors were not fully
explained by differences in cell diameter (Fig. 3f, Extended Data Fig 4b), ribosomal RNA
(Fig. 3g, Extended Data Fig. 4c, d), or total RNA content (Extended Data Fig. 3c and 4e),
which were similar among HSCs and lymphoid progenitors despite differences in protein
synthesis.
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Rpl24Bst/+ mice have a hypomorphic mutation in the Rpl24 ribosome subunit, reducing
protein synthesis in multiple cell types by 30% in culture3,4,26. Adult Rpl24Bst/+ mice are
grossly normal but are 20% smaller than wild-type mice and have mild pigmentation and
skeletal abnormalities26. These mice had normal bone marrow, spleen, and thymus
cellularity, blood cell counts (Extended Data Fig. 5a, b), and HSC frequency (Fig. 4a).
Frequencies of colony-forming progenitors (Extended Data Fig. 6b), restricted progenitors,
and Annexin V+ HSCs and MPPs (Extended Data Fig. 5c–i) were also largely normal.
OP-Puro incorporation into unfractionated bone marrow cells, HSCs, GMPs and pre-B cells
from Rpl24Bst/+ mice was significantly reduced relative to wild-type cells (Fig. 4d). OP-
Puro incorporation into Rpl24Bst/+ HSCs was reduced by approximately 30% relative to
control HSCs. Some cell populations appeared to depend more than others upon Rpl24 for
protein synthesis. Rpl24 was highly differentially expressed among haematopoietic cells
(Extended Data Fig. 5j).
Upon transplantation into irradiated mice, Rpl24Bst/+ bone marrow cells gave significantly
lower levels of donor cell reconstitution in the myeloid, B, and T cell lineages relative to
control donor cells (Fig. 4e and Extended Data Fig. 5k). We did not detect impaired homing
of Rpl24Bst/+ LSK cells to the bone marrow (Extended Data Fig. 5l). Significantly impaired
reconstitution by Rpl24Bst/+ cells was also evident in secondary recipient mice (Fig. 4f).
After Cy/G-CSF treatment, significantly fewer Rpl24Bst/+ HSCs were in S/G2/M as
compared to wild-type HSCs (Fig. 4b). HSC frequency in the bone marrow after Cy/G-CSF
treatment was 2–3 fold higher in wild-type as compared to Rpl24Bst/+ mice (Fig. 4c).
Colonies formed by individual Rpl24Bst/+ HSCs in methylcellulose contained significantly
fewer cells than wild-type HSC colonies (Extended Data Fig. 6c). Rpl24Bst/+ HSCs are thus
impaired in their proliferative potential.
Some ribosomal defects can induce p53 and its target p21cip1 (ref27). Comparing Rpl24Bst/+
versus wild-type cells, we did not detect any difference in p53 levels among Lineage−
haematopoietic progenitors (Extended Data Fig. 5m) or in p21cip1 levels among LSK cells
(Extended Data Fig. 5n). These data are consistent with prior studies28 indicating that p53
and p21cip1 are not induced in adult Rpl24Bst/+ haematopoietic cells. Moreover, loss of a
single allele of p53 did not rescue the size of colonies formed by Rpl24Bst/+ HSCs in culture
(Extended Data Fig. 6e) even though p53 heterozygosity largely rescues developmental
phenotypes in Rpl24Bst/+ embryos28. HSC defects in Rpl24Bst/+ mice are therefore not
caused by increased p53 function.
Pten deletion increases protein synthesis
HSCs had pAkt and pS6 levels that were similar to lymphoid progenitors but lower than
myeloid progenitors (Fig. 5a, Extended Data Fig. 4f). We conditionally deleted Pten from
adult haematopoietic cells in Mx1-Cre; Ptenfl/fl mice. As previously shown29–33, Pten
deletion strongly increased pAKT and pS6 levels in bone marrow cells (Fig. 5a) and in
HSCs/MPPs (Fig. 5d). Consistent with this, we observed an approximately 30% increase in
protein synthesis in Pten-deficient relative to control HSCs (p<0.01; Fig. 5b,c).
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that never develop leukaemia, by a mechanism that depends upon cell-autonomous
mTORC1 and mTORC2 activation29–32. We examined OP-Puro incorporation into HSCs
from Mx1-Cre; Rictorfl/fl mice, Mx1-Cre; Rictorfl/fl; Ptenfl/fl mice, and Mx1-Cre; Ptenfl/fl
mice. Rictor deletion (which inactivates mTORC2) had no effect on the rate of protein
synthesis in otherwise wild-type HSCs (Fig. 5c, Extended Data Fig. 6g), consistent with the
normal reconstituting capacity of Rictor-deficient HSCs30. However, Rictor deficiency
significantly reduced protein synthesis in Pten-deficient HSCs to normal levels (Fig. 5c,
Extended Data Fig. 6g). The ability of Rictor deletion to rescue both protein synthesis and
HSC function after Pten deletion30 suggested that Pten deletion depletes HSCs partly by
cell-autonomously increasing protein synthesis. Rapamycin treatment, which also prevents
HSC depletion after Pten deletion31,32, also blocked the increase in protein synthesis in
Pten-deficient HSCs (data not shown).
HSCs from Mx1-Cre; Ptenfl/fl; Rpl24Bst/+ mice had significantly less protein synthesis than
HSCs from Mx1-Cre; Ptenfl/fl mice (Fig. 5b,c). Although ribosomes can promote mTORC2
signaling34, Rpl24Bst/+ did not reduce levels of pAKT, pGSK3β, pS6, or p4E-BP1 in HSCs/
MPPs (Fig. 5d), suggesting Rpl24Bst/+ did not reduce mTORC1 or mTORC2 signaling. In
fact, Mx1-Cre; Ptenfl/fl; Rpl24Bst/+ HSCs/MPPs had slightly increased levels of pS6 and
p4E-BP1 relative to Pten-deficient HSCs/MPPs, but this would be expected to further
increase protein synthesis rather than reducing it. This suggested that Rpl24Bst/+ acted
downstream of the PI3-kinase pathway to block the increase in protein synthesis in HSCs
after Pten deletion, raising the question of whether Rpl24Bst/+ could also block
leukaemogenesis or HSC depletion.
Rpl24Bst suppresses leukaemogenesis
Conditional deletion of Pten in haematopoietic cells leads to a myeloproliferative disorder
(MPD) and T cell acute lymphoblastic leukaemia (T-ALL)31,33,35. Increased protein
synthesis promotes some haematopoietic malignancies, including T cell leukaemias3,4,6,36.
Two weeks after pIpC administration, Mx1-Cre; Ptenfl/fl mice exhibited significantly
increased spleen and thymus cellularity (Fig. 5e, f, Extended Data Fig. 6h, i), consistent with
the induction of MPD and T-ALL31,33,35. Mx1-Cre; Ptenfl/fl; Rpl24Bst/+ mice exhibited
normal spleen and thymus cellularity (Fig. 5e, f, Extended Data Fig. 6h, i), suggesting that
reduced ribosome function impaired the development of MPD and T-ALL after Pten
deletion.
To compare MPD and T-ALL development we transplanted 2×106 bone marrow cells from
each genetic background into irradiated mice then treated with pIpC four weeks later.
Recipients of Mx1-Cre; Ptenfl/fl; Rpl24Bst/+ haematopoietic cells lived significantly longer
than recipients of Mx1-Cre; Ptenfl/fl haematopoietic cells (Fig. 5g). We confirmed by PCR
that the donor cells had completely excised Pten (data not shown). When ill recipients of
cells of either genotype were sacrificed, they exhibited splenomegaly, thymomegaly and
histological signs of MPD and T-ALL (Extended Data Fig. 6k). Rpl24Bst/+ therefore
significantly (p<0.001; Fig. 5g) delayed, but did not entirely prevent, MPD and T-ALL after
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tPten deletion. It is unclear whether Rpl24Bst/+ impairs leukaemogenesis by acting within
HSCs or within other haematopoietic cells.
Pten deletion mobilizes HSCs to the spleen29,30. Rpl24Bst/+ blocked this effect, restoring
normal HSC numbers in spleens of Mx1-Cre; Ptenfl/fl; Rpl24Bst/+ mice (Extended Data Fig.
6j).
Rpl24Bst rescues Pten-deficient HSCs
We performed long-term reconstitution assays in which we transplanted 10
CD150+CD48−LSK HSCs from wild-type, Mx1-Cre; Ptenfl/fl, Rpl24Bst/+, or Mx1-Cre;
Ptenfl/fl; Rpl24Bst/+ mice along with 300,000 wild-type bone marrow cells into irradiated
wild-type mice. As expected, most (15 of 18) recipients of wild-type HSCs but no (0 of 12)
recipients of Pten-deficient HSCs were long-term multilineage reconstituted by donor cells
(Fig. 5h, i). Relative to control HSCs, Rpl24Bst/+ HSCs gave lower levels of donor cell
reconstitution in all lineages (Fig. 5h) and a somewhat lower fraction of recipients were
long-term multilineage reconstituted (10 of 19; Fig. 5i), though these differences were not
statistically significant. Relative to Pten-deficient HSCs, Mx1-Cre; Ptenfl/fl; Rpl24Bst/+
compound mutant HSCs gave significantly higher levels of reconstitution and a significantly
higher percentage of recipients were long-term multilineage reconstituted by donor cells
(Fig. 5h, i). Reconstitution by Mx1-Cre; Ptenfl/fl; Rpl24Bst/+ HSCs was statistically
indistinguishable from wild-type HSCs in all lineages except the B lineage (Pten deficiency
impairs B lineage progenitors independent of its effects on HSCs33; Fig. 5h). We confirmed
by PCR that the donor cells had completely excised Pten (data not shown). This
demonstrates that reducing protein synthesis restores the ability of Pten-deficient HSCs to
give long-term multilineage reconstitution.
Secondary transplantation of 3×106 bone marrow cells from long-term multilineage
reconstituted primary recipients in Fig. 5h yielded significantly less donor cell reconstitution
and long-term multilineage reconstitution among recipients of Rpl24Bst/+ as compared to
control HSCs (Fig. 5j and 5k). Secondary recipients of Mx1-Cre; Ptenfl/fl; Rpl24Bst/+
compound mutant HSCs also exhibited significantly less donor cell reconstitution and long-
term multilineage reconstitution as compared to control HSCs. Rpl24Bst/+ thus restored
long-term multilineage reconstituting potential to Pten deficient HSCs but did not fully
restore wild-type function. Pten deficiency thus impairs HSC function partly by increasing
protein synthesis.
To test MPP function we competitively transplanted 100 donor CD150−CD48−LSK MPPs19
from Mx-1-Cre; Ptenfl/fl, Rpl24Bst/+, or control mice into irradiated recipients. There was a
trend toward lower reconstitution by Rpl24Bst/+ MPPs and Pten-deficient MPPs relative to
control MPPs but the differences were not statistically significant (Extended Data Fig. 7a,
b). Neither Rpl24Bst/+ nor Pten deletion significantly affected the percentage of bone
marrow cells that formed colonies or the cellularity of those colonies (Extended Data Fig.
6b, d). Thus, we have not detected clear effects of Rpl24Bst/+ or Pten deletion on the
proliferative potential of MPPs or restricted progenitors, suggesting they are not as sensitive
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tas HSCs to changes in protein synthesis, though it remains possible they are also impaired
by changes in protein synthesis.
DISCUSSION
When we added HSCs to culture, OP-Puro incorporation increased dramatically (data not
shown). This raises the possibility that the failure to sustainably maintain HSCs under any
known culture conditions37 may reflect a limitation imposed by increased protein synthesis.
Consistent with this, rapamycin promotes HSC maintenance in culture38, though it remains
to be determined whether rapamycin attenuates the increase in protein synthesis in cultured
HSCs.
Low rates of protein synthesis may be essential for maintaining metabolic homeostasis in
HSCs and potentially in other kinds of somatic stem cells. Changes in protein synthesis may
cause undesirable changes in the quality and/or content of the proteome, such as due to
misfolding. There may also be changes in the translation of certain subsets of transcripts
(potentially including key HSC regulators) when protein synthesis increases, similar to what
occurs in cancer cells5.
Embryonic stem (ES) cells have high proteasome activity and proteasome activity increases
both ES cell maintenance and C. elegans lifespan39,40. Rapamycin treatment, and mutations
that reduce mTOR signaling, also increase lifespan (see citations in ref41) and would be
predicted to reduce protein synthesis. In the context of these results, our observations raise
the possibility that reduced protein synthesis and/or increased proteasome activity is
required to maintain certain long-lived somatic cells in addition to increasing organismal
lifespan.
METHODS
Mice
Rpl24Bst/+ 26, Ptenfl/fl 44, Mx1-Cre45, Rictorfl/fl 30, Abcg2 46 and p53+/− (ref 47) mutant mice
have been previously described. These mice were all backcrossed for at least eight
generations onto a C57BL background, with the exception of Abcg2−/− mice, which were on
an FVB.129 N7 background (Taconic). C57BL/Ka-Thy-1.1 (CD45.2) and C57BL/Ka-
Thy-1.2 (CD45.1) mice were used in transplantation experiments. Both male and female
mice were used in all studies. Expression of Mx1-Cre was induced by three or four
intraperitoneal injections of 10μg pIpC (GE Healthcare) administered every other day
beginning around 6 weeks of age. For cyclophosphamide and G-CSF experiments, 4mg of
cyclophosphamide (Baxter) was administered by intraperitoneal injection on day 0, and 5μg
of G-CSF (Neupogen; Amgen) was administered by subcutaneous injection on days 1 and 2.
Mice were analyzed on day 3. All mice were housed in the Unit for Laboratory Animal
Medicine at the University of Michigan (UM), where breeding for these studies was
initiated, or in the Animal Resource Center at the University of Texas (UT) Southwestern
Medical Center, where these studies were performed. All protocols were approved by the
UM Committee on the Use and Care of Animals and by the UT Southwestern Institutional
Animal Care and Use Committee.
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For in vitro analysis 103-104 bone marrow or sorted cells were plated in 100 μl of
methionine free Dulbecco’s Modified Eagle’s Medium (Sigma) supplemented with 200 μM
L-cysteine (Sigma), 50 μM 2-mercaptoethanol (Sigma), 1mM L-glutamine (Gibco) and
0.1% bovine serum albumin (BSA; Sigma). For analysis of HPG and AHA incorporation,
cells were pre-cultured for 45 minutes to deplete endogenous methionine. For OP-Puro, the
medium was supplemented with 1mM L-methionine (Sigma). HPG (Life Technologies;
1mM final concentration), AHA (Life Technologies; 1mM final concentration) or OP-Puro
(Medchem Source; 50 μM final concentration) were added to the culture medium for 1 hour
(HPG and OP-Puro) or 2.5 hours (AHA), then cells were removed from wells and washed
twice in Ca2+ and Mg2+ free phosphate buffered saline (PBS). Cells were fixed in 0.5ml of
1% paraformaldehyde (Affymetrix) in PBS for 15 minutes on ice. Cells were washed in
PBS, then permeabilized in 200 μl PBS supplemented with 3% fetal bovine serum (Sigma)
and 0.1% saponin (Sigma) for 5 minutes at room temperature. The azide-alkyne
cycloaddition was performed using the Click-iT Cell Reaction Buffer Kit (Life
Technologies) and azide conjugated to Alexa Fluor 488 or Alexa Fluor 555 (Life
Technologies) at 5μM final concentration. After the 30 minute reaction, the cells were
washed twice in PBS supplemented with 3% fetal bovine serum and 0.1% saponin, then
resuspended in PBS supplemented with 4’,6-diamidino-2-phenylindole (DAPI; 4 μg/ml final
concentration) and analyzed by flow cytometry. To inhibit OP-Puro, HPG or AHA
incorporation, cycloheximide (Sigma) was added 30 minutes prior to OP-Puro or HPG at a
final concentration of 100 μg/ml. All cultures were incubated at 37°C in 6.5% CO2 and
constant humidity.
For in vivo analysis, OP-Puro (50mg/kg body mass; pH 6.4–6.6 in PBS) was injected
intraperitoneally. One hour later mice were euthanized, unless indicated otherwise. Bone
marrow was harvested, and 3×106 cells were stained with combinations of antibodies
against cell surface markers as described below. After washing, the cells were fixed,
permeabilized, and the azide-alkyne cycloaddition was performed as described above.
“Relative rates of protein synthesis” were calculated by normalizing OP-Puro signals to
whole bone marrow after subtracting autofluorescence background. “Mean OP-Puro
fluorescence” reflected absolute fluorescence values for each cell population from multiple
independent experiments.
To assess the effect of proteasome activity on OP-Puro incorporation mice were
administered an intravenous injection of bortezomib (Cell Signaling; 1mg/kg body mass) 1
hour before OP-Puro administration. OP-Puro incorporation was assessed as described
above 1 hour later unless indicated otherwise.
Flow cytometry and cell isolation
Bone marrow cells were isolated by flushing the long bones (femurs and tibias) or by
crushing the long bones, vertebrae, and pelvic bones with a mortar and pestle in Ca2+ and
Mg2+ free Hank’s buffered salt solution (HBSS; Gibco) supplemented with 2% heat-
inactivated bovine serum (Gibco). Spleens and thymuses were prepared by crushing tissues
between frosted slides. All cells were filtered through a 40 μm cell strainer to obtain single
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tcell suspensions. Cell number and viability were assessed by a Vi-CELL cell viability
analyzer (Beckman Coulter) or by counting with a hemocytometer.
For flow cytometric analysis and isolation of specific haematopoietic progenitors, cells were
incubated with combinations of antibodies to the following cell-surface markers, conjugated
to FITC, PE, PerCP-Cy5.5, Cy5, APC, PE-Cy7, eFluor 660, Alexa Fluor 700, APC-eFluor
780, or biotin: CD2 (RM2-5), CD3ε (17A2), CD4 (GK1.5), CD5 (53-7.3), CD8α (53-6.7),
CD11b (M1/70), CD16/32 (FcΥRII/III; 93), CD24 (M1/69), CD25 (PC61.5), CD34
(RAM34), CD43 (1B11), CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD45R (B220;
RA3-6B2), CD48 (HM48-1), CD71 (C2), CD117 (cKit; 2B8), CD127 (IL7Rα; A7R34),
CD138 (281-2), CD150 (TC15-12F12.2), Ter119 (TER-119), Sca1 (D7, E13-161.7), Gr-1
(RB6-8C5), and IgM (II/41). For isolation of HSCs and MPPs, Lineage markers included
CD3, CD5, CD8, B220, Gr-1, and Ter119. For isolation of CMPs, GMPs, and MEPs, these
Lineage markers were supplemented with additional antibodies against CD4 and CD11b.
Biotinylated antibodies were visualized by incubation with PE-Cy7 or APC-Alexa Fluor 750
conjugated streptavidin. All reagents were acquired from BD Biosciences, eBiosciences, or
BioLegend. All incubations were for approximately 30 minutes on ice. HSCs, MPPs,
CD34+CD16/32lowCD127−Lineage−Sca-1−ckit+ CMPs,
CD34+CD16/32highCD127−Lineage−Sca-1−ckit+ GMPs, and
CD34−CD16/32−/lowCD127−Lineage−Sca-1−ckit+ MEPs were sometimes pre-enriched by
selecting c-kit+ cells using paramagnetic microbeads and an autoMACS magnetic separator
(Miltenyi Biotec).
Non-viable cells were excluded from sorts and analyses using DAPI. Apoptotic cells were
identified using APC Annexin V (BD Biosciences). Data acquisition and cell sorting were
performed on a FACSAria flow cytometer (BD Biosciences). All sorted fractions were
double sorted to ensure high purity. Data were analyzed by FACSDiva (BD Biosciences) or
FlowJo (Tree Star) software.
Long-term competitive repopulation assay
Adult recipient mice (CD45.1) were administered a minimum lethal dose of radiation using
an XRAD 320 X-ray irradiator (Precision X-Ray Inc.) to deliver two doses of 540 rad (1,080
rad in total) at least 3 hours apart. Cells were injected into the retro-orbital venous sinus of
anesthetized recipients. For competitive bone marrow transplants 5×105 donor and 5×105
recipient cells were transplanted. For HSC transplants 10 donor CD150+CD48−Lin−Sca1+c-
kit+ HSCs and 3×105 recipient bone marrow cells were transplanted. Blood was obtained
from the tail veins of recipient mice every 4 weeks for at least 16 weeks after
transplantation. For MPP transplants 100 donor CD150−CD48−Lin−Sca1+c-kit+ MPPs and
3×105 recipient bone marrow cells were transplanted. Blood was obtained from the tail veins
of recipient mice 3, 5 and 7 weeks after transplantation. Red blood cells were lysed with
ammonium chloride potassium buffer. The remaining cells were stained with antibodies
against CD45.2, CD45.1, CD45R (B220), CD11b, CD3, and Gr-1 to assess donor cell
engraftment. Mice that died or developed obvious haematopoietic neoplasms were omitted
from the analyses. For secondary transplants, 3×106 bone marrow cells harvested from
primary recipients were transplanted non-competitively into irradiated recipient mice.
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reconstitution by donor cells and levels of donor cell reconstitution that were typical (closest
to mean values) for the treatments from which they originated. For survival studies in Figure
5, irradiated mice were transplanted with 2×106 bone marrow cells of each genotype and
pIpC was administered 4 weeks later to delete Pten. Three to four donors per genotype were
used with 5–10 recipients per donor. Mice were sacrificed when they appeared moribund.
Western blotting
Equal numbers of cells from each stem/progenitor population (unless indicated otherwise)
were sorted into, or resuspended in, trichloracetic acid (TCA, Sigma). The final
concentration was adjusted to 10% TCA. Extracts were incubated on ice for at least 15
minutes and centrifuged at 16,100 × g at 4°C for 15 minutes. Precipitates were washed in
acetone twice and dried. The pellets were solubilized in 9M urea, 2% Triton X-100, and 1%
DTT. LDS loading buffer (Life Technologies) was added and the pellet was heated at 70°C
for 10 minutes. Samples were separated on Bis-Trispolyacrylamide gels (Life Technologies)
and transferred to PVDF membrane (Millipore). Western blotting was performed according
to the protocol from Cell Signaling Technologies and blots were developed with the
SuperSignal West Femto chemiluminescence kit (Thermo Scientific). Blots were stripped
with 1% SDS, 25 mM glycine (pH 2) prior to reprobing. The following primary antibodies
were used for western blots (obtained from Cell Signaling Technologies unless indicated
otherwise): phos-Akt (Ser473; D9E), AKT (C67E7), phos-S6 (SER240/244; polyclonal), S6
(5G10), phos-4E-BP1 (T37/46; 236B4), 4E-BP1 (polyclonal), phos-eIF2α (SER51;
polyclonal), eIF2α (D7D3), phos-GSK3β (Ser9; D85E12), β-Actin (AC-74; Sigma), p53
(cm5p; Leica), p21cip1 (F-5; Santa Cruz), and Rpl24 (polyclonal; Abcam). For p21cip1, the
membranes were treated with the SuperSignal Western Blot Enhancer (Thermo Scientific).
Band intensity was quantified with ImageJ software.
Methylcellulose cultures
200 live bone marrow cells or single CD150+CD48−LSK cells were sorted per well of a 96
well plate containing methylcellulose culture medium (M3434, Stemcell Technologies) and
incubated at 37°C in 6.5% CO2 and constant humidity. Colony formation was assessed 14
days after plating, except for Extended Data Fig. 6e where colonies were assessed 15 days
after plating. Colony size was assessed by microscopically picking individual colonies with
a pipette, washing the cells in PBS, and counting live cells by Trypan blue exclusion on a
hemocytometer.
Cell size
The average diameter of sorted cells was measured by sorting cells into flat bottom 96 well
plates and analyzing micrographs with ImageJ software.
RNA content
15,000 cells of each haematopoietic cell population were sorted into RLT Plus buffer
(Qiagen) supplemented with 2-mercaptoethanol. RNA from each sample was extracted with
the RNeasy micro plus kit (Qiagen) into 14 μl of water. 2 μl of each sample was analysed in
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tduplicate for 18S rRNA, 28S rRNA, and total RNA concentration using an Agilent RNA
6000 Pico kit and a Bioanalyzer (Agilent) at the UT Southwestern Genomics & Microarray
Core.
Protein content
50,000 cells of each population were sorted into PBS. G0/G1 cells were distinguished from
S/G2/M cells based on DNA content using Hoechst 33342 (Sigma) staining of live cells.
Cells were spun down and resuspended in 20 μl of RIPA buffer (Pierce) supplemented with
complete protease inhibitor (Roche) and rotated at 4°C for 30 minutes. Lysates were spun
down at 16,100 × g at 4°C for 15 minutes. The protein content in the supernatant was
assessed with the BCA assay (Pierce).
Statistical Methods
In all cases, multiple independent experiments were performed on different days to verify
the reproducibility of experimental findings. Group data are always represented by mean
±standard deviation. Numbers of experiments noted in figure legends reflect independent
experiments performed on different days.
To test statistical significance between two samples, two-tailed Student’s t-tests were used.
When multiple samples were compared, statistical significance was assessed using a one
way ANOVA or a repeated measures one way ANOVA (when comparing multiple time
points or populations from the same mouse) followed by Dunnett’s test for multiple
comparisons. When multiple samples were each compared to one another, statistical
significance was assessed using a one way ANOVA followed by Tukey’s t-tests for multiple
comparisons. Statistical significance comparing overall numbers of long term multilineage
reconstituted mice was assessed either by a Fisher’s exact test (Fig. 4f) or by Chi-squared
tests followed by Tukey’s t-tests for pairwise comparisons (Fig. 5i and 5k). Statistical
significance with respect to differences in survival (Fig. 5g) was calculated using a log-rank
test. The specific type of test used for each figure panel is described in the figure legends.
For normalized protein synthesis rates and normalized mRNA expression, means were
calculated and statistical tests were performed using log10 transformed data and then means
were back transformed to prevent data skewing.
No randomization or blinding was used in any experiments. The only mice excluded from
any experiment were those that developed leukaemia after transplantation in Figure 5h,i.
Since the purpose of this experiment was to compare the reconstituting capacity of normal
HSCs, the presence of leukaemia in a minority of recipient mice was a confounding factor
that had the potential to inappropriately skew the results; therefore, the experiment was
initiated with the intention of excluding data from any mouse that died during the
experiment. We excluded 0–4 mice per treatment.
In the case of measurements in which variation among experiments tends to be low (e.g.
HSC frequency) we generally examined 3–6 mice. In the case of measurements in which
variation among experiments tends to be higher (e.g. reconstitution assays) we examined
larger numbers of mice (>10). In the case of assays that assess protein synthesis, there was
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tno historical data on which to base sample sizes. In that case we performed multiple
independent experiments with multiple biological replicates to ensure the reproducibility of
our findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Quantifying protein synthesis in haematopoietic cells in vivo
a, OP-Puro incorporation in bone marrow cells in vivo one hour after administration. b-d,
OP-Puro (b), HPG (c), and AHA (d) incorporation in bone marrow cells in culture was
inhibited by cycloheximide (CHX). d, Bone marrow cells from mice treated with OP-Puro in
vivo exhibited normal AHA incorporation in culture, indicating OP-Puro did not block
protein synthesis. e,f OP-Puro versus HPG (e; n=4 mice from 2 experiments) or AHA (f;
n=3 mice from 3 experiments) incorporation by haematopoietic cells in culture. g, OP-Puro
incorporation in CD150+CD48−LSK HSCs and unfractionated bone marrow cells one hour
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tafter administration in vivo. h, Protein synthesis in various haematopoietic stem and
progenitor cell populations relative to unfractionated bone marrow cells (n=15 mice from 9
experiments). Extended Data Fig. 1j shows the data from Fig. 1h using a log2 scale. Data
represent mean±s.d. Statistical significance was assessed using two-tailed Student’s t-tests
(e-f) and differences relative to HSCs (h) were assessed using a repeated measures one way
ANOVA followed by Dunnett’s test for multiple comparisons (*, p<0.05; **, p<0.01; ***,
p<0.001 relative to bone marrow; ###, p<0.001 relative to HSCs).
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tFigure 2. Lower rate of OP-Puro incorporation by HSCs does not reflect efflux or proteasomal
degradation
a,b, OP-Puro fluorescence in haematopoietic cells from Abcg2-deficient and control mice
one hour after OP-Puro administration in vivo (n=4 mice from 3 experiments). c, OP-Puro
fluorescence in haematopoietic cells one, three, or twenty-four hours after OP-Puro
administration (n=5 experiments). d, OP-Puro fluorescence in haematopoietic cells two
hours after bortezomib and one hour after OP-Puro administration in vivo (n=5 mice/
treatment from 5 experiments). e, Western blots of 30,000 cells from each haematopoietic
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tcell population from OP-Puro-treated or control mice. f, OP-Puro fluorescence in
haematopoietic cells one hour after administering 50mg/kg or 100mg/kg OP-Puro (n=5
mice/dose from 5 experiments). All data represent mean±s.d. To assess the statistical
significance of treatment effects within the same cells we performed two-tailed Student’s t-
tests (*, p<0.05; **, p<0.01; ***, p<0.001). Differences between HSCs and other cell
populations were assessed with a repeated measures one way ANOVA followed by
Dunnett’s test for multiple comparisons (#, p<0.05; ##, p<0.01; ###, p<0.001).
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tFigure 3. HSCs synthesize less protein than most haematopoietic progenitors, even when
undergoing self-renewing divisions
a, OP-Puro incorporation in vivo in bone marrow cells in G0/G1 versus S/G2/M. b, Protein
synthesis in G0/G1 and S/G2/M cells from haematopoietic cell populations in vivo (n=10
mice from 6 experiments). We were unable to assess OP-Puro incorporation in S/G2/M
HSCs and MPPs in these experiments because these cells are extraordinarily rare in normal
bone marrow. c, Protein synthesis in haematopoietic cells after Cy/G-CSF treatment (n=10
mice from 6 experiments). d,e, Protein synthesis in G0/G1 (d) and S/G2/M (e) cells from
Cy/G-CSF-treated mice (n=10 mice from 6 experiments). Extended Data Fig. 3f–g show the
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tdata from Fig. 3d–e side-by-side with data from untreated controls in Fig. 3b. f, Cell
diameter (n>60 cells/population from 2 mice). g, 18S rRNA and 28S rRNA content in
15,000 cells from each stem/progenitor cell population (n=3 mice). All data represent mean
±s.d. To assess the statistical significance of treatment effects within the same cells (b-c) we
performed two-tailed Student’s t-tests (*, p<0.05; **, p<0.01; ***, p<0.001) and differences
between HSCs and other cells (b-g) were assessed with a repeated measures one-way
ANOVA followed by Dunnett’s test for multiple comparisons (#, p<0.05; ##, p<0.01; ###,
p<0.001).
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tFigure 4. Rpl24Bst/+ HSCs synthesize less protein and have less capacity to reconstitute
irradiated mice
a, Frequencies of HSCs and MPPs in Rpl24Bst/+ (n=7) versus littermate control (n=6) mice
(n=5 experiments). b,c Frequency of HSCs in S/G2/M (b; n=4 untreated mice/genotype, n=3
(Rpl24Bst/+) or 4 (+/+) Cy/G-CSF treated mice/genotype in 3 experiments) and frequency of
HSCs in the bone marrow (c; n=6 wild-type and 7 Rpl24Bst/+ untreated mice, n=7 wild-type
and 5 Rpl24Bst/+ Cy/G-CSF treated mice in 4 experiments) after treatment with Cy/G-CSF.
d, Protein synthesis in haematopoietic cells based on OP-Puro incorporation in vivo (n=4
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tmice/genotype in 4 experiments). e, Donor cell engraftment when 5×105 donor bone marrow
cells were transplanted along with 5×105 recipient bone marrow cells into irradiated
recipient mice (n=4 experiments with a total of 17 recipients for wild-type, and 20 for
Rpl24Bst/+; myeloid, B, and T engraftment are in Extended Data Figure 5k). f, The number
of long-term multilineage reconstituted secondary recipients (>0.5% donor myeloid and
lymphoid cells for at least 16 weeks after transplantation) after secondary transplantation of
3×106 bone marrow cells from primary recipients in (e) (n=4 donors/genotype). All data
represent mean±s.d. Statistical significance was assessed with two-tailed Student’s t-tests (a-
e) and Fisher’s exact test (f) (*p<0.05, **p<0.01, ***p<0.001). Differences between HSCs
and other cell populations (d) were assessed with a repeated measures one-way ANOVA
followed by Dunnett’s test for multiple comparisons (#, p<0.05; ##, p<0.01; ###, p<0.001).
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tFigure 5. Rpl24Bst/+ blocks the increase in protein synthesis and restores HSC function after
Pten deletion
a, Western blots of 30,000 cells from each population. Long and short exposures for pS6 are
shown. For total S6, a non-specific band is present below the specific band. Differences in
β-Actin represent differences in β-Actin content per cell (1 representative blot from two
experiments). b, Representative histograms of OP-Puro fluorescence in HSCs of each
genotype. c, OP-Puro incorporation into HSCs of each genotype (n=15 experiments). d,
Western blots of 30,000 HSCs/MPPs of the indicated genotypes (1 representative blot from
two experiments). e, Representative spleens 2 weeks after pIpC administration to wild-type,
Mx-1-Cre; Ptenfl/fl, Rpl24Bst/+, and Mx-1-Cre; Ptenfl/fl; Rpl24Bst/+ mice. f, Spleen and
thymus cellularity (n=7 experiments). g, Time until mice had to be sacrificed due to illness
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tafter transplantation of 2×106 bone marrow cells of the indicated genotypes into irradiated
recipient mice. h, i, 10 donor HSCs were transplanted along with 3×105 recipient bone
marrow cells into irradiated recipients. Donor cell engraftment (h) and fraction of recipients
that were long-term multilineage reconstituted (i; 3 experiments). j, k, Donor cell
engraftment (j) and the fraction of secondary recipients that were long-term multilineage
reconstituted (k) after transplantation of 3×106 bone marrow cells from primary recipients in
(h) (n=4 donors/genotype). All data represent mean±s.d. Differences among genotypes (c, f,
h) were assessed with a one way ANOVA followed by Dunnett’s test for multiple
comparisons. Statistical significance was assessed by log-rank test (g), Chi-squared tests
followed by Tukey's t-tests for pairwise comparisons (i,k), or a one way ANOVA followed
by Tukey’s t-tests for multiple comparisons (j). Significance was expressed relative to wild-
type (#, p<0.05; ##, p<0.01; ###, p<0.001) or Pten-deficient cells (*, p<0.05; **, p<0.01;
***, p<0.001).
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